{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:22Z","timestamp":1792788082370,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Malm\u00f6 University","id":[{"id":"https:\/\/ror.org\/05wp7an13","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Motivational Interviewing and Medication Review in Coronary Heart Disease (MIMeRiC) randomized controlled trial investigated the effects of a pharmacist-led intervention at a cardiology clinic on patient adherence and clinical outcomes. The results demonstrated that the intervention group had increased adherence to cholesterol-lowering medications and aspirin, as well as improved overall beliefs about medicines. However, the intervention did not lead to a higher proportion of patients reaching the target for low-density lipoprotein cholesterol (LDL-C) levels. This paper reports on the implementation of the intervention and explores potential mechanisms underlying these outcomes, focusing on the content of medication reviews, quality of prescribing, and changes in beliefs about medicines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medication reviews were evaluated by classification of identified drug-related problems (DRPs), actions taken to address these problems, and the outcomes of those actions, utilizing data from electronic health records (EHR). The Medication Assessment Tool for secondary prevention of Coronary Heart Disease (MAT-CHDsp) was applied to EHR data to evaluate prescribing quality. Beliefs about medicines were evaluated using the Beliefs about Medicines Questionnaire specific (BMQ-S), completed by participants at baseline and follow-up. Descriptive and comparative statistics were used to analyze the data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Medication reviews were conducted for 144 of the 159 patients in the intervention group, with a mean of 4.3 DRPs per patient. Pharmacists identified 500 DRPs and managed 245 of these with patients alone, while 196 required discussions with physicians. The resulting status of 218 DRPs was known, and for 194 of these, the issue was solved or improved. No differences in prescribing quality were observed between groups at six months post-discharge. The mean concern score on the BMQ-S decreased more in the intervention group, and 52.8% of intervention patients vs. 31.0% of control patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.051) shifted from an ambivalent to an accepting attitudinal category.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This process evaluation demonstrates that clinical pharmacists were effective in identifying and managing DRPs through collaboration with patients and physicians, leading to the resolution or improvement of a substantial number of DRPs. The intervention did not impact prescription quality. Patients in the intervention group reported reduced concerns about their medications, which explains the improved medication adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>This study is based on data from a randomized controlled trial (RCT) registered at ClinicalTrials.gov (NCT02102503; registered 03\/04\/2014).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-026-15037-5","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:33:43Z","timestamp":1789493623000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of a pharmacist adherence intervention on medication beliefs and drug-related problems in coronary patients \u2013 a process evaluation of the MIMeRiC trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Malin Johansson","family":"\u00d6stbring","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9526-4109","authenticated-orcid":false,"given":"Ahmed","family":"Al Musawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Hellstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"4","key":"15037_CR1","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.ahj.2007.12.011","volume":"155","author":"PM Ho","year":"2008","unstructured":"Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155(4):772\u20139.","journal-title":"Am Heart J"},{"issue":"2","key":"15037_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1001\/jama.297.2.177","volume":"297","author":"JN Rasmussen","year":"2007","unstructured":"Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177\u201386.","journal-title":"JAMA"},{"key":"15037_CR3","doi-asserted-by":"crossref","unstructured":"Svensson MK, Sorio Vilela F, Le\u00f3sd\u00f3ttir M, Banefelt J, Lindh M, Dun AR, Norhammar A, Villa G. Effects of lipid-lowering treatment intensity and adherence on cardiovascular outcomes in patients with a recent myocardial infarction: a Swedish register-based study. Ups J Med Sci. 2022;127.","DOI":"10.48101\/ujms.v127.8296"},{"issue":"14","key":"15037_CR4","doi-asserted-by":"publisher","first-page":"e025813","DOI":"10.1161\/JAHA.122.025813","volume":"11","author":"F Mazhar","year":"2022","unstructured":"Mazhar F, Hjemdahl P, Clase CM, Johnell K, Jernberg T, Sj\u00f6lander A, Carrero JJ. Intensity of and Adherence to Lipid-Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease. J Am Heart Assoc. 2022;11(14):e025813.","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"15037_CR5","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1177\/2047487316663873","volume":"23","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Corra U, Dendale P, Frederix I, Prescott E, Schmid JP, Cupples M, Deaton C, Doherty P, Giannuzzi P, et al. Challenges in secondary prevention after acute myocardial infarction: A call for action. Eur J Prev Cardiol. 2016;23(18):1994\u20132006.","journal-title":"Eur J Prev Cardiol"},{"issue":"15","key":"15037_CR6","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1136\/heartjnl-2017-312571","volume":"104","author":"RH Fuller","year":"2018","unstructured":"Fuller RH, Perel P, Navarro-Ruan T, Nieuwlaat R, Haynes RB, Huffman MD. Improving medication adherence in patients with cardiovascular disease: a systematic review. Heart. 2018;104(15):1238\u201343.","journal-title":"Heart"},{"issue":"10","key":"15037_CR7","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1177\/2047487316638501","volume":"23","author":"K Santo","year":"2016","unstructured":"Santo K, Kirkendall S, Laba TL, Thakkar J, Webster R, Chalmers J, Chow CK, Redfern J. Interventions to improve medication adherence in coronary disease patients: A systematic review and meta-analysis of randomised controlled trials. Eur J Prev Cardiol. 2016;23(10):1065\u201376.","journal-title":"Eur J Prev Cardiol"},{"issue":"7","key":"15037_CR8","doi-asserted-by":"publisher","first-page":"e036575","DOI":"10.1136\/bmjopen-2019-036575","volume":"10","author":"C Fitzpatrick","year":"2020","unstructured":"Fitzpatrick C, Gillies C, Seidu S, Kar D, Ioannidou E, Davies MJ, Patel P, Gupta P, Khunti K. Effect of pragmatic versus explanatory interventions on medication adherence in people with cardiometabolic conditions: a systematic review and meta-analysis. BMJ open. 2020;10(7):e036575.","journal-title":"BMJ open"},{"key":"15037_CR9","first-page":"h1258","volume":"350","author":"GF Moore","year":"2015","unstructured":"Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, Moore L, O\u2019Cathain A, Tinati T, Wight D, et al. Process evaluation of complex interventions: Medical Research Council guidance. BMJ (Clinical Res ed. 2015;350:h1258.","journal-title":"BMJ (Clinical Res ed"},{"key":"15037_CR10","doi-asserted-by":"crossref","unstructured":"Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, Boyd KA, Craig N, French DP, McIntosh E, et al. A new framework for developing and evaluating complex interventions: update of medical research council guidance. BMJ (Clinical Res ed). 2021;374:n2061.","DOI":"10.1136\/bmj.n2061"},{"issue":"1","key":"15037_CR11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12872-021-02178-0","volume":"21","author":"MJ \u00d6stbring","year":"2021","unstructured":"\u00d6stbring MJ, Eriksson T, Petersson G, Hellstr\u00f6m L. Effects of a pharmaceutical care intervention on clinical outcomes and patient adherence in coronary heart disease: the MIMeRiC randomized controlled trial. BMC Cardiovasc Disord. 2021;21(1):367.","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"15037_CR12","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.2196\/resprot.8659","volume":"7","author":"MJ \u00d6stbring","year":"2018","unstructured":"\u00d6stbring MJ, Eriksson T, Petersson G, Hellstr\u00f6m L. Motivational Interviewing and Medication Review in Coronary Heart Disease (MIMeRiC): Protocol for a Randomized Controlled Trial Investigating Effects on Clinical Outcomes, Adherence, and Quality of Life. JMIR Res Protoc. 2018;7(2):e57.","journal-title":"JMIR Res Protoc"},{"issue":"1","key":"15037_CR13","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.2196\/resprot.8660","volume":"7","author":"MJ \u00d6stbring","year":"2018","unstructured":"\u00d6stbring MJ, Eriksson T, Petersson G, Hellstr\u00f6m L. Motivational Interviewing and Medication Review in Coronary Heart Disease (MIMeRiC): Intervention Development and Protocol for the Process Evaluation. JMIR Res Protoc. 2018;7(1):e21.","journal-title":"JMIR Res Protoc"},{"key":"15037_CR14","doi-asserted-by":"crossref","unstructured":"Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-Related Problems: Their Structure and Function. DICP. 1990;24(11):1093\u20137.","DOI":"10.1177\/106002809002401114"},{"key":"15037_CR15","unstructured":"Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care practice: the patient centered approach to medication management. 3 ed. New York McGraw-Hill, Health Professions Division; 2012."},{"issue":"3","key":"15037_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/pds.2054","volume":"20","author":"BH Garcia","year":"2011","unstructured":"Garcia BH, Utnes J, Naalsund LU, Giverhaug T. MAT-CHDSP, a novel medication assessment tool for evaluation of secondary prevention of coronary heart disease. Pharmacoepidemiol Drug Saf. 2011;20(3):249\u201357.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"15037_CR17","doi-asserted-by":"crossref","unstructured":"Garcia BH, Smabrekke L, Trovik T, Giverhaug T. Application of the MAT-CHD(SP) to assess guideline adherence and therapy goal achievement in secondary prevention of coronary heart disease after percutaneous coronary intervention. Eur J Clin Pharmacol. 2012.","DOI":"10.1007\/s00228-012-1402-7"},{"issue":"12","key":"15037_CR18","doi-asserted-by":"publisher","first-page":"e80633","DOI":"10.1371\/journal.pone.0080633","volume":"8","author":"R Horne","year":"2013","unstructured":"Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients\u2019 adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS ONE. 2013;8(12):e80633.","journal-title":"PLoS ONE"},{"issue":"1","key":"15037_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08870449908407311","volume":"14","author":"R Horne","year":"1999","unstructured":"Horne R, Weinman J, Hankins M. The Beliefs about Medicines Questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14(1):1\u201324.","journal-title":"Psychol Health"},{"issue":"3","key":"15037_CR20","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s11096-024-01702-4","volume":"46","author":"A Al Musawi","year":"2024","unstructured":"Al Musawi A, Hellstr\u00f6m L, Axelsson M, Midl\u00f6v P, R\u00e4mg\u00e5rd M, Cheng Y, Eriksson T. Intervention for a correct medication list and medication use in older adults: a non-randomised feasibility study among inpatients and residents during care transitions. Int J Clin Pharm. 2024;46(3):639\u201347.","journal-title":"Int J Clin Pharm"},{"key":"15037_CR21","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2147\/PPA.S197481","volume":"13","author":"A Sieben","year":"2019","unstructured":"Sieben A, van Onzenoort HA, van Dulmen S, van Laarhoven C, Bredie SJ. A nurse-based intervention for improving medication adherence in cardiovascular patients: an evaluation of a randomized controlled trial. Patient Prefer Adherence. 2019;13:837\u201352.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"15037_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40266-016-0429-3","volume":"34","author":"CY Lin","year":"2017","unstructured":"Lin CY, Yaseri M, Pakpour AH, Malm D, Brostrom A, Fridlund B, Burri A, Webb TL. Can a Multifaceted Intervention Including Motivational Interviewing Improve Medication Adherence, Quality of Life, and Mortality Rates in Older Patients Undergoing Coronary Artery Bypass Surgery? A Multicenter, Randomized Controlled Trial with 18-Month Follow-Up. Drugs Aging. 2017;34(2):143\u201356.","journal-title":"Drugs Aging"},{"issue":"1","key":"15037_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijcard.2011.04.025","volume":"161","author":"B Libungan","year":"2012","unstructured":"Libungan B, Stensdotter L, Hjalmarson A, From Attebring M, Lindqvist J, B\u00e4ck M, Herlitz J. Secondary prevention in coronary artery disease. Achieved goals and possibilities for improvements. Int J Cardiol. 2012;161(1):18\u201324.","journal-title":"Int J Cardiol"},{"issue":"1","key":"15037_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.amjcard.2013.09.007","volume":"113","author":"K Hambraeus","year":"2014","unstructured":"Hambraeus K, Lindhagen L, Tyd\u00e9n P, Lindahl B, Lagerqvist B. Target-attainment rates of low-density lipoprotein cholesterol using lipid-lowering drugs one year after acute myocardial infarction in sweden. Am J Cardiol. 2014;113(1):17\u201322.","journal-title":"Am J Cardiol"},{"issue":"6","key":"15037_CR25","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s11096-013-9841-5","volume":"35","author":"J Krska","year":"2013","unstructured":"Krska J, Morecroft CW, Poole H, Rowe PH. Issues potentially affecting quality of life arising from long-term medicines use: a qualitative study. Int J Clin Pharm. 2013;35(6):1161\u20139.","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"15037_CR26","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s11096-018-0601-4","volume":"40","author":"DM van der Laan","year":"2018","unstructured":"van der Laan DM, Elders PJM, Boons C, Nijpels G, Krska J, Hugtenburg JG. The impact of cardiovascular medication use on patients\u2019 daily lives: a cross-sectional study. Int J Clin Pharm. 2018;40(2):412\u201320.","journal-title":"Int J Clin Pharm"},{"key":"15037_CR27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2147\/PPA.S230120","volume":"14","author":"MJ \u00d6stbring","year":"2020","unstructured":"\u00d6stbring MJ, Hellstr\u00f6m L, M\u00e5rtensson J. Trivial or Troublesome: Experience with Coronary Heart Disease Medication from the Patient\u2019s Perspective. Patient Prefer Adherence. 2020;14:411\u201324.","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"15037_CR28","doi-asserted-by":"publisher","first-page":"e069770","DOI":"10.1136\/bmjopen-2022-069770","volume":"13","author":"M Leosdottir","year":"2023","unstructured":"Leosdottir M, Hagstrom E, Hadziosmanovic N, Norhammar A, Lindahl B, Hambraeus K, Jernberg T, B\u00e4ck M. Temporal trends in cardiovascular risk factors, lifestyle and secondary preventive medication for patients with myocardial infarction attending cardiac rehabilitation in Sweden 2006\u20132019: a registry-based cohort study. BMJ Open. 2023;13(5):e069770.","journal-title":"BMJ Open"},{"issue":"8","key":"15037_CR29","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1177\/2047487318825350","volume":"26","author":"K Kotseva","year":"2020","unstructured":"Kotseva K, De Backer G, De Bacquer D, Ryd\u00e9n L, Hoes A, Grobbee D, Maggioni A, Marques-Vidal P, Jennings C, Abreu A, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2020;26(8):824\u201335.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"15037_CR30","doi-asserted-by":"publisher","first-page":"575","DOI":"10.18549\/PharmPract.2015.02.575","volume":"13","author":"BH Garcia","year":"2015","unstructured":"Garcia BH, Giverhaug T, H\u00f8gli JU, Skjold F, Sm\u00e5brekke L. A pharmacist-led follow-up program for patients with established coronary heart disease in North Norway - a randomized controlled trial. Pharm Pract (Granada). 2015;13(2):575.","journal-title":"Pharm Pract (Granada)"},{"issue":"3","key":"15037_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267\u2013315.","journal-title":"Eur Heart J"},{"issue":"2","key":"15037_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119\u201377.","journal-title":"Eur Heart J"},{"issue":"18","key":"15037_CR33","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1177\/2047487318806359","volume":"25","author":"J Ferrieres","year":"2018","unstructured":"Ferrieres J, De Ferrari GM, Hermans MP, Elisaf M, Toth PP, Horack M, Brudi P, Lautsch D, Bash LD, Baxter CA, et al. Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe. Eur J Prev Cardiol. 2018;25(18):1966\u201376.","journal-title":"Eur J Prev Cardiol"},{"key":"15037_CR34","unstructured":"\u00d6stbring MJ. Pharmaceutical care in coronary heart disease. Linnaeus university. 2021."},{"key":"15037_CR35","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3389\/fphar.2018.01057","volume":"9","author":"DM van der Laan","year":"2018","unstructured":"van der Laan DM, Elders PJM, Boons C, Nijpels G, van Dijk L, Hugtenburg JG. Effectiveness of a Patient-Tailored, Pharmacist-Led Intervention Program to Enhance Adherence to Antihypertensive Medication: The CATI Study. Front Pharmacol. 2018;9:1057.","journal-title":"Front Pharmacol"},{"issue":"4","key":"15037_CR36","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s11096-019-00845-z","volume":"41","author":"DM van der Laan","year":"2019","unstructured":"van der Laan DM, Langendoen-Gort M, Nijpels G, Boons C, Elders PJM, Hugtenburg JG. Implementation fidelity of an intervention programme to enhance adherence to antihypertensive medication in Dutch community pharmacies. Int J Clin Pharm. 2019;41(4):1031\u201346.","journal-title":"Int J Clin Pharm"},{"issue":"9","key":"15037_CR37","doi-asserted-by":"publisher","first-page":"e0183963","DOI":"10.1371\/journal.pone.0183963","volume":"12","author":"D Huber","year":"2017","unstructured":"Huber D, Henriksson R, Jakobsson S, Mooe T. Nurse-led telephone-based follow-up of secondary prevention after acute coronary syndrome: One-year results from the randomized controlled NAILED-ACS trial. PLoS ONE. 2017;12(9):e0183963.","journal-title":"PLoS ONE"},{"issue":"6","key":"15037_CR38","first-page":"485","volume":"21","author":"DF Blackburn","year":"2005","unstructured":"Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk WM. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol. 2005;21(6):485\u20138.","journal-title":"Can J Cardiol"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-15037-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-15037-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-15037-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:29:20Z","timestamp":1789745360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-15037-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15037"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-15037-5","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the Regional Ethics Committee in Link\u00f6ping, Sweden (Dnr-2013\/236\u2009\u2212\u200931) for the randomized controlled trial (RCT) that serves as the basis of this process evaluation. All participants in the RCT were provided with verbal and written information about the study and were included after giving written informed consent. Data were handled in accordance with the Swedish Patient Data Act and the routines of the Region Kalmar County. The data were de-identified and securely stored in locked cabinets.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1283"}}